Ftse Mib
34.511,00
-0,90%
DAX
18.684,40
-0,44%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
70.949,24
-0,70%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ATAI Life Sciences NV (ATAI) ATAI Life Sciences NV (ATAI) Notizie

ATAI

ATAI Life Sciences NV (ATAI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATAI
DataOraFonteTitoloSimboloCompagnia
20/05/202423:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
15/05/202413:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATAIATAI Life Sciences NV
15/05/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
15/05/202412:59GlobeNewswire Inc.atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ATAIATAI Life Sciences NV
24/04/202413:00GlobeNewswire Inc.atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
17/04/202413:00GlobeNewswire Inc.atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyNASDAQ:ATAIATAI Life Sciences NV
28/03/202412:00GlobeNewswire Inc.atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsNASDAQ:ATAIATAI Life Sciences NV
27/03/202412:00GlobeNewswire Inc.atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
04/03/202414:00GlobeNewswire Inc.atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01NASDAQ:ATAIATAI Life Sciences NV
28/02/202423:00GlobeNewswire Inc.atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceNASDAQ:ATAIATAI Life Sciences NV
13/02/202422:29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATAIATAI Life Sciences NV
06/02/202423:00GlobeNewswire Inc.atai Life Sciences Appoints Anne Johnson as Chief Financial OfficerNASDAQ:ATAIATAI Life Sciences NV
04/01/202413:00GlobeNewswire Inc.atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration PsychedelicsNASDAQ:ATAIATAI Life Sciences NV
02/01/202414:00GlobeNewswire Inc.atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)NASDAQ:ATAIATAI Life Sciences NV
14/11/202313:03GlobeNewswire Inc.atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsNASDAQ:ATAIATAI Life Sciences NV
10/10/202314:00PR Newswire (Canada)ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORTNASDAQ:ATAIATAI Life Sciences NV
06/10/202322:05GlobeNewswire Inc.atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:ATAIATAI Life Sciences NV
02/10/202322:13GlobeNewswire Inc.atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsNASDAQ:ATAIATAI Life Sciences NV
14/09/202314:02GlobeNewswire Inc.atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:ATAIATAI Life Sciences NV
06/09/202322:01GlobeNewswire Inc.atai Life Sciences to Participate in Upcoming September Investor ConferencesNASDAQ:ATAIATAI Life Sciences NV
10/08/202312:59GlobeNewswire Inc.atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)NASDAQ:ATAIATAI Life Sciences NV
08/08/202322:02GlobeNewswire Inc.atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)NASDAQ:ATAIATAI Life Sciences NV
01/06/202315:10GlobeNewswire Inc.Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerNASDAQ:ATAIATAI Life Sciences NV
01/06/202312:59GlobeNewswire Inc.atai Life Sciences to Participate in Upcoming June Investor ConferencesNASDAQ:ATAIATAI Life Sciences NV
31/05/202313:56Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATAIATAI Life Sciences NV
25/05/202322:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATAIATAI Life Sciences NV
19/05/202323:37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ATAIATAI Life Sciences NV
11/05/202322:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATAIATAI Life Sciences NV
11/05/202312:59GlobeNewswire Inc.atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and UpdatesNASDAQ:ATAIATAI Life Sciences NV
02/05/202323:20GlobeNewswire Inc.atai Life Sciences to Participate in Upcoming May Investor ConferenceNASDAQ:ATAIATAI Life Sciences NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATAI

La tua Cronologia

BIT
SPM
Saipem
BIT
G
Generali
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BPE
Bper Banca
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
CPR
Davide Campari
BIT
TEN
Tenaris
BIT
BPSO
Banca Popolare di Sondrio
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network